Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EBITDA (2021 - 2025)

Prime Medicine filings provide 5 years of EBITDA readings, the most recent being -$46.0 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 8.83% to -$46.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$201.1 million, a 2.65% decrease, with the full-year FY2025 number at -$201.1 million, down 2.65% from a year prior.
  • EBITDA hit -$46.0 million in Q4 2025 for Prime Medicine, up from -$50.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$16.4 million in Q3 2021 to a low of -$65.5 million in Q4 2023.
  • Median EBITDA over the past 5 years was -$45.9 million (2024), compared with a mean of -$44.2 million.
  • The widest YoY moves for EBITDA: up 37.69% in 2022, down 80.96% in 2022.
  • Prime Medicine's EBITDA stood at -$62.9 million in 2021, then surged by 37.69% to -$39.2 million in 2022, then crashed by 67.06% to -$65.5 million in 2023, then soared by 35.43% to -$42.3 million in 2024, then fell by 8.83% to -$46.0 million in 2025.
  • The last three reported values for EBITDA were -$46.0 million (Q4 2025), -$50.5 million (Q3 2025), and -$52.6 million (Q2 2025) per Business Quant data.